



BostonBioForum 2014

CABA 2014 ANNUAL CONFERENCE

二〇一四美中生物医药协会年会

Biomedical Industry - The Next Decade

生物医药产业 —— 下一个十年


Time: 8:30 AM to 9:00 PM (Saturday, May 3, 2014)

Venue: The Doubletree Suites by Hilton Hotel Boston

Address: 400 Soldiers Field Road, Allston, MA 02134

Featured Topics

- *Small vs big molecules vs macrocyclics, RNAi, and other emerging technologies for future therapeutics*
- *Bridging the valley of death - How can academia and pharma best work together? and innovation in pharma business models*
- *Factors for a successful IPO*
- *Are Chinese CROs losing allure? - Strategy to move forward*



BostonBioForum 2014

CABA 2014 ANNUAL CONFERENCE

二〇一四美中生物医药协会年会

Biomedical Industry - The Next Decade

生物医药产业 —— 下一个十年

Themes/Topics

- **Small vs big molecules vs macrocyclics, RNAi and other emerging technologies for future therapeutics**
- **Bridging the valley of death - How can academia and pharma best work together? and innovation in pharma business models**
- **Factors for a successful IPO**
- **Is Chinese CRO losing allure? - Strategy to move forward**

Admission

CABA members: FREE; Non-members: \$30. On-site enrollment to be CABA member is available

*Dinner reception: \$40. Dinner pre-registration required. Limited tickets available
Complimentary garage parking*

Conference Organizing Committee

Chair

HOWARD LI

Co-Chairs

SUSAN QU

YIKAI WANG

ZHIYONG YANG

Committee Memembers

QINGQING CAO
JO LEE
BO YING

QINGLIN CHE
SHIWEN LIN
XIANG YANG YU

YIN CHEN
CARRIE LIU

ELLEN FAN
ERIC SHI

AGENDA

- ▶ 8:00-9:00 Registration
- ▶ 9:00-9:05 Opening Remarks

MORNING SESSION I – Better Academia/Industry Interface

SESSION CHAIR: Howard Li

- 9:05-9:35 **New Adaptive Models to Support Healthcare Innovation (Keynote)**
Robert Urban, PhD, Head, Johnson & Johnson Innovation Center, Boston
- 9:35-10:05 **Entrepreneurial Drug Hunter: Exploring Peptide Drug Space at the Industry-Academia Interface**
Tomi Sawyer, PhD, Entrepreneurial Drug Hunter, Adjunct Professor, Univ. of Massachusetts, Northeastern Univ.
- 10:05-10:35 **Drug Discovery & Development Efforts at the Belfer Institute for Applied Cancer Science at DFCI**
Jessie English, PhD, Head of Research, Belfer Institute for Applied Cancer Science, DFCI



- 10:35-10:50 Coffee Break and Vendor Show

MORNING SESSION II – Modality Diversity

SESSION CHAIR: Yikai Wang

- 10:50-11:20 **Talking Dirty: The Case for Polypharmacological Approaches to Drug Discovery**
Kerry Spear, PhD, VP & Head of Chemistry, Sunovion Pharmaceuticals; Adjunct Professor of Medicinal Chemistry, Fudan University, China
- 11:20-11:50 **Discovery and Development of Allosteric Inhibitors of Phosphoryl-transferring Enzymes**
Tom Chan, PhD, President, Allosta Pharmaceuticals
- 11:50-12:20 **Exploring Macrocycles for Drug Discovery: Novel Lead Series for Challenging Protein-Protein Interactions**
Nick Terrett, PhD, CSO, Ensemble Therapeutics



- 12:20-1:30 Lunch Break and Vendor Show

AFTERNOON SESSION I – R&D Services

SESSION CHAIRS: Wendy Yang, Min Zhong

- 1:30-1:45 **From a StartUp to Mass Innovation Labs**
PC Zhu, PhD, President, Mass Innovation Labs; CEO, NeoBioLabs
Amrit Chaudhuri, PhD, CEO, Mass Innovation Labs
Seth Taylor, PhD, MBA, Chief Commercial Officer, Mass Innovation Labs
- 1:45-2:00 **IP Strategy for Biotech and Pharmaceutical Companies**
Fangli Chen, PhD, JD, Partner, Choate Hall & Stewart LLP.
Henry Gu, PhD, JD, Director, Intellectual Property Counsel, Cubist Pharmaceuticals

2:00-2:40 Panel Discussion
Moderators: Wendy Yang, Min Zhong

Jinbo Lee, PhD, CSO, Scilligence
Jennifer Kuo, PhD, New England Regional Manager, DiscoverRX
Tony Li, COO, Wyzer Biosciences
Xian Bu, PhD, Founder/Managing Director, SYNthesis
Zonghui Peng, PhD, Deputy Director of Pharmacogenomics Research, BGI
Huanming Chen, PhD, VP of Chemistry, Medicilon
Jason Xiang, PhD, Executive Director, Discovery Chemistry Services, ChemPartner
Ruo Xu, PhD, General Manager, Chemspec-API



2:40-3:00 Coffee Break and Vendor Show
(Sponsored by BGI)



AFTERNOON SESSION II – IPO Stories

SESSION CHAIR: Susan Qu

3:00-3:35 **Concert Pharmaceuticals: Taking a Multi-pronged Approach to the Public Markets**
Roger Tung, PhD, CEO, Concert Pharmaceuticals
3:35-4:10 **Queuing up for an IPO**
Douglas Fambrough, PhD, CEO, Dicerna Pharmaceuticals
4:10-4:45 **The IPO Experience - Wall Street Chemistry**
David Lubner, CFO, Tetraphase Pharmaceuticals



5:00-6:00 Cocktail Social Hour: Networking and Vendor Show
(Sponsored by NeoBioLab)



EVENING SESSION

SESSION CHAIR: Shiwen Lin

6:00-6:15 **Summarize CABA 2013-14 and Announce the New Leadership Team**
Xiangyang Yu, PhD, Consultant, Eutropics Pharmaceuticals
6:15-6:55 **Divide and Conquer: Orphanizing All Diseases (Keynote)**
Andrew Lo, PhD, Charles E. and Susan T. Harris Professor of Finance, MIT Sloan School of Management



7:00-8:00 Dinner



Chinese-American BioMedical Association (CABA)
Organizing Committee of Boston BioForum 2014 – CABA Annual Conference

Excellence in Innovation

Concert Pharmaceuticals

In recognition of its innovative entrepreneurship
in drug development and application of stable non-radioactive isotopes
May 3, 2014
Boston, Massachusetts, USA



Chinese-American BioMedical Association (CABA)
Organizing Committee of Boston BioForum 2014 – CABA Annual Conference

Committed Sponsor

Sundia MediTech

In recognition of its consistent support to
CABA and the bio/pharmaceutical community
May 3, 2014
Boston, Massachusetts, USA





Chinese-American BioMedical Association (CABA)
Organizing Committee of Boston BioForum 2014 – CABA Annual Conference

Excellence in Innovation

Andrew Lo, PhD, Charles E. & Susan T Harris Professor,
Sloan School of Management, MIT

In recognition of his innovative and multi-disciplinary approach
of financial engineering to healthcare advancement

May 3, 2014

Boston, Massachusetts, USA

LEADERSHIP IN COMMUNITY SERVICE AWARDS

XIANG YU, PHD

LIXIN SHEN, PHD

SUE MA, MD

DEDICATED COMMUNITY SERVICE AWARDS

HAO LI, PHD, MBA

YUTONG JIN

ZHENDONG ZHU, PHD

ZHIGANG WANG, PHD

YIKAI WANG, PHD



New Adaptive Models to Support Healthcare Innovation (Keynote)

Robert Urban, PhD, Head, Johnson & Johnson Innovation Center, Boston

Robert joined Johnson & Johnson from MIT in 2012, where he was the founding Executive Director of the Koch Institute for Integrative Cancer Research. In this leadership role, Robert worked to build the Koch Institute into new standard for interdisciplinary disease-focused research via an expanding, highly-effective, relationship network with other academic oncology centers, industrial partners, cancer-focused philanthropists and investors. During Robert's tenure, the Koch Institute launched seventeen start-up companies and its technology was the source of over 50 out-licensing transactions. Before joining MIT, He was the President and CEO of Acretia Inc. – a product acquisition and out-licensing company. During his time at Acretia Inc. the organization conducted technical due diligence on more than 280 product opportunities and completed the acquisition of three distinct product lines. Prior to this, Robert held a variety of business development and clinical development roles in the pharmaceutical industry. Robert received his Bachelor of Arts degree in Microbiology and his Ph.D. in Microbiology and Immunology from the University of Texas system, and was an Irvington Fellow in structural immunology at Harvard University.



Drug Discovery & Development Efforts at the Belfer Institute for Applied Cancer Science at DFCI

Jessie English, PhD, Head of Research, Belfer Institute for Applied Cancer Science, DFCI

Dr. English joined the Belfer Institute for Applied Cancer Science at the Dana-Farber Cancer Institute in January of 2012 where she is Head of Research. The mission of the Belfer Institute is to integrate academic, industry and clinical resources/expertise to enhance success in oncology drug discovery. Previously Dr. English served as the Vice President of Kinase Biology at ArQule, where she had responsibilities spanning target identification through product candidate selection and development support. Prior to ArQule, she was the oncology site lead for external discovery at Merck Research Laboratories, where she was responsible for driving drug discovery programs through external scientific collaborations with industrial and academic partners. Earlier in her career, Dr. English held leadership positions at the Pfizer Research Technology Center as Head of the Kinase COE and in Oncology at Schering-Plough Research Institute. She earned her B.S. with honors in biochemistry from Kansas State University and her Ph.D. in neurobiology from the University of North Carolina at Chapel Hill. She was a postdoctoral fellow at UT Southwestern Medical Center, Dallas, where she discovered a novel mammalian MAPK pathway through the discovery and characterization of MEK5. Dr. English also discovered the WNK gene family that was subsequently determined to be responsible for a hereditary form of hypertension.

Entrepreneurial Drug Hunter: Exploring Peptide Drug Space at the Industry-Academia Interface

Tomi Sawyer, PhD, Entrepreneurial Drug Hunter, Adjunct Professor, Univ. of Massachusetts, Northeastern Univ.



Tomi is an entrepreneurial drug hunter with 33 years of pharma/biotech multidisciplinary drug discovery expertise via the Upjohn Company, Parke-Davis/Warner-Lambert, Pfizer Global R&D, ARIAD Pharmaceuticals and, most recently, AILERON Therapeutics (as the founding Chief Scientific Officer). He is well-known for in the fields of GPCR, kinase, protease and protein-protein interaction drug discovery. Tomi has two marketed drugs, including Scenesse® (a peptide superagonist of MCR1 for the treatment of the orphan skin disease known as erythropoietic protoporphyria and other related indications) and Iclusig® (a small-molecule inhibitor of Bcr-Abl kinase for the treatment of resistant forms of chronic myelogenous leukemia) and many other drug development contributions (e.g., Ditekiren, Ridaforolimus, ALRN-5281 and ALRN-6924). He is credited with more than 500 scientific publications, patents, and presentations and holds several Adjunct Professorships at the University of Massachusetts, the University of Massachusetts Medical School and Northeastern University Center for Drug Discovery.

Talking Dirty: The Case for Polypharmacological Approaches to Drug Discovery

Kerry Spear, PhD, VP & Head of Chemistry, Sunovion Pharmaceuticals; Adjunct Professor of Medicinal Chemistry, Fudan University, China



Dr. Spear is Vice President of Medicinal Chemistry at Sunovion Pharmaceuticals, a Pharma company headquartered in Marlborough, MA. He is currently in charge of all medicinal chemistry efforts within Sunovion's discovery research department. Trained in natural products synthesis, he has over 30 years of experience as a medicinal chemist in both the pharmaceutical and the biotechnology industries. He has participated in or led programs that cover a broad range of drug discovery research and which have resulted in the acceptance 10 IND applications and 3 CTA applications in multiple therapeutic areas. Specific areas of expertise include the ability to interface medicinal chemistry, computational chemistry, phenotypic drug design, multi-target drug design, structure-based drug design, combinatorial chemistry, pharmacology, ADME and related disciplines in order to accelerate drug discovery and lead optimization processes. He also actively manages multidisciplinary outsourcing efforts at an international level to accelerate timelines and reduce costs while maintaining quality. Dr. Spear completed a postdoctoral fellowship at the University of California, Berkeley. He received a Ph.D. degree in organic chemistry from the University of Wisconsin, Madison and a B.S. degree in chemistry from Juniata College.



Discovery and Development of Allosteric Inhibitors of Phosphoryl-transferring Enzymes

Tom Chan, PhD, President, Allosta Pharmaceuticals

Dr. Thomas Chan is a founder and President of Allosta Pharmaceutical, a new biopharmaceutical company focused on the design and development of allosteric enzyme inhibitors. He was the Chief Scientific Officer and Senior Vice President of Discovery and Development at ArQule, Inc., where he was responsible for drug discovery against novel disease targets, preclinical development, and translational medicine to progress development candidates through Phase 1 clinical testing. Before joining ArQule in 2005, he was Vice President of R&D and Chief Technology Officer of MacroChem Corporation, a specialty pharmaceutical company. Dr. Chan has held positions of increasing responsibility in the biotechnology industry since 1992. Prior to joining the industry, Dr. Chan's academic appointments included service as a Director of the Purdue Cancer Center, and he held a tenured professorship at Purdue/Indiana Universities from 1983-1992. Dr. Chan earned an undergraduate degree in Biochemistry, and MD/PhD from the University of British Columbia. He completed a fellowship in Hematology/Oncology at the University of California, San Diego Cancer Center.

Abstract:

Many human enzymes that regulate cellular functions utilize phosphate transfer as a biochemical on-off switch. Protein kinases have become favorite targets for drug development. Indeed, the discovery and clinical development of inhibitors of kinase function have shown to be a productive endeavor. Currently, there are more than a dozen kinase inhibitors approved for commercial sale in the US, the majority of them are ATP mimetics. Most of these inhibitors compete for binding to the highly conserved ATP recognition region of the active site of kinases, and they are often referred to as multi-kinase inhibitors. The inhibition of off-target kinases can translate into substantial toxic side effects which can halt development and preclude the combination of kinase inhibitors with other chemotherapeutics. Allosteric inhibitors that bind to sites away from the active sites of enzymes may yield more selective and less toxic inhibitors. Advances in the understanding of protein dynamics and the increasing use of in silico methods, together with wider deployment of biophysical assays and structure-based drug discovery techniques, can be efficiently combined in the discovery and development of allosteric inhibitors. This approach has provided new avenues for enzyme inhibitor design and played a role in the prosecution of targets that have been traditionally considered "un-druggable".



Exploring Macrocycles for Drug Discovery: Novel Lead Series for Challenging Protein-Protein Interactions

Nick Terrett, PhD, CSO, Ensemble Therapeutics

Abstract:

Macrocycles are found widely in nature and several of these natural products are marketed as drugs with good drug-like properties. As it is difficult to readily generate analogs of complex natural products, the popularity of synthetic macrocycles for drug discovery has been steadily increasing. This presentation will illustrate how Ensemble can rapidly generate millions of synthetic macrocycles using DNA-programmed chemistry, and how these compounds can be efficiently screened against protein-protein interaction targets to identify hit compounds and SAR information. The novel approach will be illustrated with successful examples of lead discovery programs at Ensemble, including the discovery of novel XIAP and IL17A antagonists.

Nick Terrett was born in London, England and educated at the University of Cambridge (MA, PhD). During his career Nick has had extensive experience working as a drug discovery chemist in both the pharmaceutical and biotech sectors. Nick was lead chemist and inventor for the program that discovered sildenafil citrate (Viagra™) the world's first oral therapy for male erectile dysfunction, and also marketed for pulmonary hypertension (Revatio™). He established Pfizer's combinatorial chemistry group, and published in the mid-1990s on this new technology including writing the first single author text book. During his time at Pfizer, Nick was also responsible for high throughput screening and the materials management groups, playing a central role in the integration of the Warner-Lambert and Pharmacia compound collections. Following a move to the US, Nick was Senior Director and Head of Chemical Sciences at Pfizer, Cambridge MA. Since 2006 he has been Chief Scientific Officer for Ensemble Therapeutics, a drug discovery biotech company in Cambridge, MA. Nick is also an advisor for several biotech companies and the Chemical Abstracts Service of the American Chemical Society.



From a StartUp to Mass Innovation Labs

PC Zhu, PhD, President, Mass Innovation Labs; CEO, NeoBioLabs

New England Journal of Medicine, and The Harvard Gazette. In addition, his inventions have been used by leading biotechnology companies including Life Technologies and Alnylam Pharmaceuticals. Dr. Zhu also holds an MBA degree from the Chicago Booth Business School. Dr. Zhu founded NeoBioLab in 2008, establishing research facilities in Massachusetts, along with branches in the

Dr. P.C. Zhu is an entrepreneur and scientist in the fields of biotechnology and pharmaceuticals. He has extensive experience in biomedical research and commercial development. He holds a Ph.D. in Molecular Genetics and has many years of research experience in neuroscience, HIV, immunology and drug delivery. His scientific achievements at Harvard Medical School have been praised by headline news items in journals such as Nature, Nature Reviews, The

United Kingdom, China, and India. NeoBiolab not only provides life science services, but also performs R&D in the fields of peptide synthesis, antibody development, and vaccines. Previously, Dr. Zhu has co-founded the GENE Group, a leading company providing lab management solutions that has recently attracted outside investments. Dr. Zhu has made significant contributions to the life science community by creating the Boston Biotech Club and founding the CSSA at Harvard Medical School. Currently, Dr. Zhu is developing Mass Innovation Labs, a platform to help biological entrepreneurs accelerate commercialization of their scientific innovations. Dr. Zhu enjoys traveling, hiking, skiing and movies. The Boston Red Sox are his favorite team.

IP Strategy for Biotech and Pharmaceutical Companies

*Fangli Chen, PhD, JD, Partner,
Choate Hall & Stewart LLP.*



*Henry Gu, PhD, JD, Director, Intellectual
Property Counsel, Cubist Pharmaceuticals*



Fangli Chen represents clients in strategic development of complex patent portfolios, including preparing and prosecuting patent applications; due diligence investigations; freedom-to-operate studies; non-infringement and invalidity analysis; and foreign opposition proceedings. She has a strong business sense and deep scientific expertise and is able to effectively identify and transform technological developments into valuable intellectual property assets for her clients. Dr. Chen has been named an "Up & Coming Lawyer" by Massachusetts Lawyers Weekly and a Massachusetts Super Lawyers Rising Star. Dr. Chen received a BS, with highest distinction, in Genetics from Fudan University (Shanghai, China) in 1990, a MS in Plant Pathology from Oklahoma State University in 1995, a PhD in Biology from the Massachusetts Institute of Technology in 2001, and a JD, cum laude, from Suffolk University Law School in 2006.

Henry Gu is Director, Senior IP Counsel at Cubist Pharmaceuticals located in Lexington, MA. Henry has extensive experience in the areas of IP litigation, patent prosecution, IP counseling, patentability assessments, freedom-to-operate, competitive landscape analyses, due diligence, and non-infringement and invalidity opinion. Prior to joining Cubist, Henry was Counsel in the Intellectual Property Department of WilmerHale, a prominent international law firm. Henry served as counsel to many sectors of the chemical, pharmaceutical, biotechnology and clean energy industries, including start-up, mid-size, and well-established, multi-national companies. His practice focused on patent prosecution, opinion, due diligence, IP strategy, and pharmaceutical patent litigation. He also assisted clients with all aspects of their IP rights in China, including procurement and enforcement of patent rights. Henry is president of the Chinese American Intellectual Property Law Association. He is a frequent speaker on IP protection, enforcement, and strategy.

PANEL DISCUSSION SPEAKERS



*Jinbo Lee, PhD,
CSO, Scilligence*

*Jennifer Kuo, PhD,
New England
Regional Manager,
DiscoveRX*



Jennifer Kuo is the New England Regional Manager for DiscoveRx, a privately held company focusing on providing premiere products and services for both target-based and phenotypic drug discovery and development. Previously she was at Millipore, Upstate/Chemicon, Sigma Aldrich. Jennifer received a B.A. from Cornell University and a Ph.D. from Yale University.

Dr. Jinbo Lee is the co-founder and Chief Scientific Officer of Scilligence Corporation. He has extensive experience in drug discovery and development in both pharmaceutical and biotech companies with senior leadership positions. Most recently as the Head of Chemistry at Ensemble Therapeutics, he was responsible for molecule modeling/cheminformatics, medicinal chemistry, process chemistry, and analytical chemistry. Prior to Ensemble Discovery, Dr. Lee led multi-discipline teams including medicinal chemists, X-ray crystallographers, molecular modelers, pharmacologists and DMPK scientists at Wyeth Pharmaceuticals. He has also worked at Boehringer Ingelheim Pharmaceuticals in the areas of medicinal chemistry, combinatorial chemistry and parallel synthesis. Dr. Lee has in-depth knowledge in multiple diseases areas including oncology, metabolic diseases, neurodegenerative diseases, infectious diseases, and inflammatory and autoimmune diseases. He is an expert in research informatics, medicinal chemistry, structure-based drug design and prodrug design. Dr. Lee received his Ph.D. degree in Organic Chemistry from Princeton University. He was the year 1997 recipient of Roche Award for Excellence in Organic Chemistry. Dr. Lee has many publications in prestigious scientific journals and holds a number of patent/patent applications. He has been an invited speaker in numerous drug discovery and scientific conferences.



**Tony Li, COO,
Wyzer Biosciences**

Tony Li, Co-founder and COO, Wyzer Biosciences, Inc. 85 Bolton Street, STE120/121/143, Cambridge, MA 02140. Mr. Tony Li and his partners founded Wyzer Biosciences in 2011 with the original intention to provide Sanger DNA sequencing services only as CRO. Soon after Wyzer Biosciences rapidly expanded into offering DNA prep for all scales, gene synthesis and next generation DNA sequencing on Ion Torrent and Illumina platforms. Mr. Li got his bachelor degree in 1987 in Jinan University in China, majoring Bio-engineering. In 1990 he came to US as a visiting scholar in the department of human genetics, Dr. Sherman Weissman's lab at Yale Medical School. Since 1993 he was in charge of the Markey sequencing core facility at Yale's Boyer Center. In 1998, Mr. Li joined Genetics Institute, which later became part of R&D division of Wyeth/Pfizer. During the 13 years, he progressed from the associate scientist to a senior scientist II where he was mainly responsible for the operation and method developments for Sanger DNA sequencing. In addition he was instrumental in developing state-of-the-art LIMS supporting drug discovery including late stages of clinical trials. Currently Mr. Li is in charge of daily operations at Wyzer Biosciences and is responsible for the technology development and its deliverables quality assurance.

Dr. Bu is the founder and managing director of SYNthesis med chem, including the group company's

wholly-owned subsidiaries in China. Xian previously served as Vice President for the Chinese chemistry service company, and worked as a Senior Drug Discovery Scientist at Cytopia where he has co-authored more than 10 patents and contributed to push two drugs into clinical trials. Dr Bu has been a highly-motivated entrepreneur with both scientific expertise and business knowledge, and has excellent track record of scientific achievements and business management. Dr Bu is an accomplished medicinal chemist in his own right and has been involved in drug discovery research for many years. He has strong scientific expertise in the drug discovery and development area, especially in design and development of small molecules as drugs for oncology and cardiovascular diseases. He has also demonstrated remarkable talent in the management of CRO companies, and has outstanding track record of growing and expanding business for small companies.

**Xian Bu, PhD, Founder &
Managing Director, SYNthesis
med chem**



**Zonghui Peng,
PhD, Deputy
Director of
Pharmacogenomics
Research, BGI**

Zonghui Peng (Peng Z), in 2007 he got bachelor degree in bio-engineering from Dalian University. After

that, he received the master degree in microbiology from South China University of Technology on 2010. In the same year, he came and joins BGI. From 2011, as the project manager, he has been involved all the commercial & collaboration projects from top 10 pharma and also maintained efficient communication with big pharma. In addition, he has leading the group to collaborate with CRO, pharma and hospitals on the PDX study.

At present, Peng Z leads a team with 16 fellows providing multi-omics solutions and integrative informatics analysis to pharmaceuticals and bio-tech, meanwhile, he has been coordinating the group members to build and run the assays independently to shoot the targets of partner.

Dr. Chen obtained his Ph.D in Medicinal Chemistry from China Pharmaceutical University. Dr. Chen joined Shanghai Medicilon in Aug 2013. Before joining Medicilon, Dr. Chen was the Head of Shanghai R&D Center at Simcere Pharmaceutical Group. Prior to Simcere, Dr. Chen worked at BioDuro as a Senior Director of Medicinal Chemistry. Dr. Chen has extensive experience in leading drug discovery projects including key intellectual property development, hit-to-lead-to-candidate development, rational and structure-based drug design, optimization of ADMET and pharmacological properties of preclinical drug candidates, top-performing team management. Dr. Chen also served at Valeant and Ardea Biosciences as Senior Principal Scientist.



**Huanming
Chen, PhD, VP
of Chemistry,
Medicilon**



**Jason Xiang, PhD,
Executive Director,
Discovery
Chemistry
Services,
ChemPartner**

Dr. Jason Xiang has 13 years of drug discovery experience with Pfizer/Wyeth in multiple therapeutic areas including inflammatory diseases, oncology, cardiovascular and metabolic syndrome, and CNS, two years experiences in Novel BioTherapeutics including ADC and therapeutic peptide. He also has extensive experience in chemistry project initiation, high throughput screen hit evaluation, hit to lead, lead optimization and development, together with demonstrated ability to lead multi-functional project team, successfully advanced HSD-016 to clinical trial. Dr. Jason Xiang Currently manage an organization with 180 scientists.



Ruo Xu, Ph. D.
General Manager
Chemspec-API Inc.

Dr. Ruo Xu received his B.S. degree from Beijing University, Beijing, China and Ph.D. from Columbia University, New York. After brief postdoctoral work at University of California at Berkeley, he joined Schering Plough as a medicinal chemist in 1998. After the merger of Merck and Schering-Plough in 2010, he joined Global Strategic Operations and managed the outsourcing activities in the discovery and preclinical areas. Currently, he is the general manager of Chemspec-API Inc.

IPO DISCUSSION SPEAKERS



Concert Pharmaceuticals: Taking a Multi-pronged Approach to the Public Markets

Roger Tung, PhD, CEO, Concert Pharmaceuticals

Roger Tung, Ph.D. is the scientific founder, President, and CEO of Concert Pharmaceuticals, Inc. Prior to Concert, Roger worked in venture-backed start-up and major pharmaceutical companies including Vertex Pharmaceuticals, as a founding scientist and most recently as Vice President of Drug Discovery; as well as Merck & Co. and E.R. Squibb & Sons. Roger has overseen the discovery of four marketed drugs with over \$2.5B composite sales to date: Kalydeco® for cystic fibrosis, Incivek® for hepatitis C infection, and Agenerase® and Lexiva® for HIV infection. Roger is an active inventor with over 70 issued US patents and has authored or co-authored over 100 scientific papers, book chapters, and abstracts. Roger received a B.A. in Chemistry from Reed College and a Ph.D. in Medicinal Chemistry at the University of Wisconsin-Madison. Roger serves as a scientific advisor to several biotech companies and is a member of the Board of Visitors of the University of Wisconsin-Madison School of Pharmacy.

Dr. Douglas Fambrough co-founded Dicerna in 2007 and currently serves as the Company's chief executive officer. Prior to taking the CEO role at Dicerna, Dr. Fambrough was a General Partner with the Boston-based life science venture capital firm Oxford Bioscience Partners where for 10+ years he specialized in financing innovative life science technology companies. His investments include first generation RNA Interference pioneer Sirna Therapeutics, organized by Dr. Fambrough and two other investors in 2000, and where he served on their Board of Directors until the company was acquired by Merck for \$1.1 billion in 2006. Other investments include Solexa, developer of the dominant ultra-high-throughput DNA sequencing platform, acquired by Illumina for \$600 million; and Cambrios Technologies, which invented and now markets biologically-inspired electronic materials for touch screens and flat panel displays. Before joining Oxford, he was a genomic scientist at the Whitehead/MIT Center for Genome Research (now known as the Broad Institute). Dr. Fambrough graduated from Cornell University and obtained his Ph.D. in Genetics at the University of California, Berkeley.

Abstract:

Concert Pharmaceuticals (NASDAQ: CNCE) is the leader in the broad application of deuterium medicinal chemistry to create novel small molecule drugs. In our experience, selective substitution of deuterium for hydrogen, or deuteration, of biologically active compounds does not affect their pharmacological properties. However, in select cases, deuteration can improve pharmacokinetic or metabolic characteristics and thereby provide the potential for enhanced safety, tolerability or efficacy. Concert's development pipeline includes up to five compounds that are anticipated to be in clinical testing by the end of 2014. These include two wholly-owned, potential first-in-class compounds: CTP-499, a Phase 2 compound for diabetic kidney disease, and CTP-354, a Phase 1 compound for spasticity. Additional development candidates include CTP-730, partnered with Celgene for inflammatory disease; JZP-386, a deuterated analog of sodium oxybate, the active ingredient Xyrem®, partnered with Jazz Pharmaceuticals for narcolepsy; and AVP-786, which contains a deuterated analog of dextromethorphan the active ingredient in Nuedexta®, partnered with Avanir Pharmaceuticals. The commercial potential of Concert's pipeline compounds, the breadth of our DCE Platform®, and validation of the technology by multiple partnerships were key elements underpinning a successful initial public offering.

Queuing up for an IPO

Douglas Fambrough, PhD, CEO, Dicerna Pharmaceuticals



The IPO Experience - Wall Street Chemistry

David Lubner, CFO, Tetrphase Pharmaceuticals

David C. Lubner has served as Tetrphase's Senior Vice President and Chief Financial Officer since October 2010 and from its inception in 2006 until October 2010 he served on a part-time basis as its Senior Vice President and Chief Operating Officer. Mr. Lubner also served as Chief Financial Officer of Mediphase Venture Partners, a venture capital firm, from 2006 until October 2010. From 1999 to 2005, he served as Vice President and Chief Financial Officer at PharMetrics, Inc., a pharmacy and medical

claims data informatics company, until its acquisition by IMS Health in 2005. Prior to joining PharMetrics, Mr. Lubner served as Vice President and Chief Financial Officer of ProScript, Inc., a biotechnology company, from 1996 to 1999. Mr. Lubner is a member of the American Institute of CPAs and is a certified public accountant in the Commonwealth of Massachusetts. Mr. Lubner received a B.S. in business administration from Northeastern University and an M.S. in Taxation from Bentley University.

DINNER RECEPTION KEYNOTE

**Divide and Conquer: Orphanizing All Diseases (Keynote)**

Andrew Lo, PhD, Charles E. and Susan T. Harris Professor of Finance, MIT Sloan School of Management

Andrew W. Lo, a prominent economist, is the Charles E. and Susan T. Harris Professor at the MIT Sloan School of Management and director of the MIT Laboratory for Financial Engineering. He received his Ph.D. in economics from Harvard University in 1984. He has published numerous articles in finance and economics journals, and has authored several books including *The Econometrics of Financial Markets*, *A Non-Random Walk Down Wall Street*, *Hedge Funds: An Analytic Perspective*, and *The Evolution of Technical Analysis*. He is currently co-editor of the *Annual Review of Financial Economics* and an associate editor of the *Financial Analysts Journal*, the *Journal of Portfolio Management*, and the *Journal of Computational Finance*. He is regarded as one of the most important innovators in finance. He has devised financing strategies to fund cancer and orphan drug discovery and development with reduced aggregate risk and increased return on investment. His campaign to employ the financial engineering tools to cure deadly diseases has been well-received. In 2012, *Time* magazine named him one of the world's 100 most influential people.

Thank you for coming and have a great evening!



PLATINUM SPONSOR



GOLD SPONSORS



SILVER SPONSORS



CONFERENCE SPONSORS



MEDIA PARTNERS



Scan each QR code to explore more!

2014-2015 CABA LEADERSHIP TEAM

President (2014-2015)

Zhiyong Yang, Ph.D.
Sr. Principal Scientist, Pfizer
BioTherapeutics Research

President-elect (2015-2016)

Susan Qu, Ph.D. MBA
Principal Project Manager, Genzyme
Corporation, a division of Sanofi

Immediate Past President (2013-2014)

Xiang Yang Yu, Ph.D.

Vice President

Qinglin Che, Ph.D.
Sr. Scientist, Synta Pharmaceuticals

General Manager of Public Relations

Qingqing Cao, Ph.D.
Senior Engineer, Becton Dickinson
(BD)-Bioscience

General Manager of Operations

Ellen Fan
Sr. Scientist, Arsenal Medical

Treasurers

Zhendong Zhu, Ph.D.
Principal Scientist, Celgene
Avilomics Research

Liping Zhou, Ph.D.

Sr. Scientist, Ispen Biopharmaceuticals

CABA Legal Counsel

Fred Gilman, J.D.
Attorney, Lynch, DeSimone & Nysten, LLP

Board of Directors

Shiwen Lin, Ph.D.
Chairman of the Board
Associate Director, Process & Analytical
Technologies, Agenus, Inc.

Chaoyang Dai, Ph.D.
CABA President (2010-2011)
VP of Operations, Acebright, Inc.

Jun Han, Ph.D.
CABA Founding President
CEO, SOTA International LLC

Lixin Shen, Ph.D.
President and CEO, Wuxi Howfond Biopharma
Co., Ltd.(China)

Zhao-Kui Wan, Ph.D.
CABA President (2009-2010)
Head of Medicinal Chemistry, Janssen
Pharmaceutical Companies of Johnson &
Johnson(China)

Yihan Wang, Ph.D.
Past Board Chair
President, Boston iBio, Inc.

Erxi Wu, Ph.D.
Assistant Prof., North Dakota State University

Junjun Wu, Ph.D.
CABA President (2007-2009)
CEO, WuXi AllNature Biotech LLC(China)

Zhihong Chen, Ph.D.
CABA President (2011-2012)

Philip Zhang, Ph.D., J.D.
CABA President (2012-2013)
Co-Managing Principal, Milstein Zhang & Wu LLC

CABA Advisors

Youssef Bennani, Ph.D.
Vice President/Discovery Chemistry,
Vertex Pharmaceuticals Inc.

Tim Clackson, Ph.D.
President of Research and Development
and Chief Scientific Officer, Ariad
Pharmaceuticals Inc.

Yuan-Hua Ding, Ph.D.
Senior Director & Head of External R&D
Innovation - Asia, Pfizer

Pierre Dodion, M. D., MBA
Sr. VP, Corporate Development, Ariad
Pharmaceuticals Inc.

Chen Li, Ph.D.
CEO, Hua Medicine (China)

Luke Li, Ph.D.
Exec Director, Head of Global Biothera-
peutic Technologies, Bio-Innovation,
Pfizer

Yuanli Liu, Ph.D.
Director of China Initiative, Harvard
School of Public Health

Dawei Ma, Ph.D.
Professor, Shanghai Institute of Organic
Chemistry (China)

Tarek Mansour, Ph.D.
EVP of Research & Development, Xenon
Pharmaceuticals (Canada)

Shi Li, Ph.D.
CEO, Zerun Biotechnology (China)

Tse Ping
Chairman, Sino Biopharmaceutical
Ltd.(China)

John Piwinski, Ph.D.
Principal, JJPiwinski Pharma Consulting
LLC

Steve Projan, Ph.D.
Sr. V.P. R&D, Innovative Medicines Head of
Infectious Diseases & Vaccines,
MedImmune

Tomi Sawyer, Ph.D.
Chief Scientific Officer and Senior
Vice-President, Aileron Therapeutics

Liming Shao, Ph.D.
Professor, Fudan University (China)

Suvit Thaisrivongs, Ph.D.
Vice President, Pfizer

Roger Tung, Ph.D.
CEO, Concert Pharmaceuticals
Yibin Xiang, Ph.D.

Gangfeng Xu, Ph.D.
Divisional Vice President, Corporate
Licensing & Acquisitions at Abbott
Laboratories

Steve Yang, Ph.D.
Head of R&D, Asia & Emerging Markets,
AstraZeneca

Howard Yuwen, Ph.D.
Executive Director, Regulatory North
America, Alexion Pharmaceuticals

Executive Committee Members

Lan Cao, Ph.D.
Fellow, Advanced Therapy, Process Development, Novartis

Yin Chen, Ph.D.
Biotech Consultant

Kevin Fang, Ph.D.
Sr. Director of Medicinal Chemistry,
Sunovion Pharmaceuticals

Henry Gu, J.D.
Director, IP Counsel at Cubist Pharmaceuticals

Jeff Hang, Ph.D.
Regulatory & Quality System Consultant, Makromed Inc.

Fred Hu, Ph.D.
Executive Director, Discovery Chemistry Services,
ChemPartner

Shengfang Jin, Ph.D.
Sr. Director/Biology, Agios Pharmaceuticals

Jinbo Lee, Ph.D.
Cofounder & CSO, Scilligence Corp.

Jo Lee
Sr. Director of BD & Marketing, Howfond, Inc.

Hao (Howard) Li, Ph.D., MBA
Cambridge Site Head, Novartis Knowledge Center, Novartis

Carrie Liu, Ph.D.
Principal Scientist, Ironwood Pharmaceuticals

Sue Ma, M.D.
Scientist II, Novartis Institute of BioMedical Research

Eric Shi, Ph.D.
Investigator, GSK

Ji Shi
Associate Analyst, Cowen and Company

Wendy Wang, MBA
Sr. Project Manager, Genzyme Corporation, a division of
Sanofi

Yikai Wang, Ph.D.
Research Fellow, The Broad Institute

Yongzhong Wang, Ph.D.
Deputy General Manager, Kanghong Biotechnology Co.,
Ltd.(China)

Yueming Wang, MBA
Deputy General Manager, Tide Pharmaceutical Co.
Ltd.(China)

Zhigang Wang, Ph.D.
Principal Scientist, Celgene Avilomics Research

Shallwei Sun
General Manager, Callisyn Biomedical

Ze Tian, Ph.D., M.D.
Staff Scientist, Curis Inc.

Li Xing, Ph.D.
Senior principal scientist, Pfizer

Jingzhong (Jeff) Zhang, Ph.D.
Sr. Scientist, Medica Corp.

Wei Zhang, Ph.D.
Staff Scientist, Siemens Healthcare Diagnostics

Weiyei (Wendy) Zhang, Ph.D.
President, Boston Lincoln International

Youxin Zhang, Ph.D.
Senior Consultant, Navigant Consulting

Chinese-American BioMedical Association

美 中 生 物 医 药 协 会

To promote science, technology, and business collaboration in biotech/pharmaceutical industry;

To build and maintain a platform through cohesive scientific, professional, and cultural connection that provides high quality services;

To facilitate networking among scientists, professionals, and entrepreneurs in academia, biotech/pharmaceutical industry and regulatory agencies;

To embrace advancement of science and commercialization of innovation that will benefit human health;

To foster collaborations between the United States and China for the development of better pharmaceutical therapeutics.

CABA

About CABA

CABA is a 501(C)(3) not-for-profit professional organization registered in Massachusetts since May 2007. CABA is committed to promote public awareness of advancement in the pharmaceutical and biomedical industry, professional interactions in the fields of life sciences, global biomedical innovations and business development. As the majority of its members are scientists with Chinese heritage, CABA will operate in two important areas. One is to serve as a platform for its members to develop and advance their careers in the US pharmaceutical and biomedical industry, the other is to serve as a bridge to connect members including corporate members with the scientific and business resources in China thus facilitating collaboration between the pharmaceutical and biomedical industries across continents. To fulfill these goals, we will organize scientific and business symposia, conferences, workshops, in US and China, as well as social events to promote networking and communication among members. We will bring together members, scientists, professionals, government officials and business leaders across the continents under a collaborative environment and achieve their best potential.

CABA is a volunteer-based society. We rely on members to contribute their time and efforts to build the organization. We rely on corporate members and sponsors to raise fund to support the above activities. We value integrity, honesty, professionalism, community service, scientific excellence, responsibility and accountability. We invite you to explore our organization, and we are confident you will share our values and are interested in becoming a member, devoting your time or efforts, or sponsoring CABA activities. In summary, CABA is built by its members and serves its members.

Contact Us

If you have any comments, suggestions or feedback to our organization and our events, please feel free to contact us at cabaconnect@gmail.com. Your comments are important for us to improve in the future. Thank you very much!

Website: www.cabaweb.org
Email: cabaconnect@gmail.com
Address: P. O. Box 600241,
Newtonville, MA 02460



Find us on:

